Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 72.6% during the third quarter, Holdings Channel reports. The fund owned 58,020 shares of the company’s stock after buying an additional 24,396 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.06% of Laboratory Corporation of America Holdings worth $7,977,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Garrison Financial Corp boosted its stake in shares of Laboratory Corporation of America Holdings by 0.5% in the second quarter. Garrison Financial Corp now owns 22,400 shares of the company’s stock valued at $2,918,000 after buying an additional 119 shares during the last quarter. Bartlett & Co. LLC boosted its stake in shares of Laboratory Corporation of America Holdings by 2.2% in the second quarter. Bartlett & Co. LLC now owns 141,528 shares of the company’s stock valued at $18,437,000 after buying an additional 2,985 shares during the last quarter. Speece Thorson Capital Group Inc. boosted its stake in shares of Laboratory Corporation of America Holdings by 1.4% in the second quarter. Speece Thorson Capital Group Inc. now owns 122,002 shares of the company’s stock valued at $15,893,000 after buying an additional 1,675 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Laboratory Corporation of America Holdings by 33.5% in the second quarter. American Century Companies Inc. now owns 367,152 shares of the company’s stock valued at $47,829,000 after buying an additional 92,232 shares during the last quarter. Finally, Argyle Capital Management Inc. bought a new stake in shares of Laboratory Corporation of America Holdings during the second quarter valued at $209,000. 91.23% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Laboratory Corporation of America Holdings (NYSE:LH) traded down 0.10% during mid-day trading on Friday, reaching $134.51. The company’s stock had a trading volume of 73,941 shares. The firm has a market capitalization of $13.85 billion, a price-to-earnings ratio of 21.33 and a beta of 0.95. Laboratory Corporation of America Holdings has a 52 week low of $97.79 and a 52 week high of $141.32. The company’s 50-day moving average price is $128.19 and its 200 day moving average price is $132.99.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, October 26th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.29 by $0.04. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.38 billion. Laboratory Corporation of America Holdings had a return on equity of 16.97% and a net margin of 6.85%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.07 EPS. On average, equities analysts forecast that Laboratory Corporation of America Holdings will post $8.80 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the propert of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this report can be accessed at http://www.watchlistnews.com/zurcher-kantonalbank-zurich-cantonalbank-has-7977000-stake-in-laboratory-corporation-of-america-holdings-lh/1059848.html.

Several research analysts have issued reports on the company. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $153.00 target price for the company in a research report on Tuesday, October 4th. Mizuho boosted their target price on Laboratory Corporation of America Holdings from $132.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, September 15th. Canaccord Genuity set a $140.00 target price on Laboratory Corporation of America Holdings and gave the company a “buy” rating in a research report on Sunday, October 30th. Finally, Gabelli assumed coverage on Laboratory Corporation of America Holdings in a research report on Tuesday, October 25th. They set a “buy” rating and a $180.00 target price for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $143.13.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.